VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Patient risk stratification in CLL and selection of treatment approaches

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, discusses patient risk stratification in chronic lymphocytic leukemia (CLL), drawing focus on the role of TP53 mutation, del(17p), and IgHV mutational status, and how these prognostic factors influence treatment approaches. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter